Fairvalue-Calculator Fairvalue-Calculator
EN DE

Easywell Biomedicals, Inc (1799) Fair Value & Analysis

Healthcare · TW · Market cap 3.8B TWD

Price30.60 TWD
Fair Value10.41 TWD
Upside-66.0%
Quality94/100
Evidence: Medium Range 6.99 TWD – 13.83 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Easywell Biomedicals, Inc (1799) currently trades at 30.60 TWD, while our model-based Fair Value estimate is 10.41 TWD — implying the stock looks roughly 66.0% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-017 for the treatment of chronic angina; and TLX-011 for the treatment of inflammatory lesions of rosacea. It is also developing TLX-015, a medicine for the prevention and treatment of postpartum hemorrhage; TLX-018, a hemorrhage treatment drug; TLX-030, a medication for adrenal insufficiency treatment; TLX-047, a systemic corticosteroid; HH-001, a sacubitril/valsartan sodium tablet; TLX-024, a liquid oral anticonvulsant; TLX-034, an endocrine drug; TWB-201, a Parkinson patch; TLX-501, a urinary medicine; and TLX-…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Easywell Biomedicals, Inc (1799) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 10.41 TWD versus a price of 30.60 TWD — about −66% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1799?
Our 21-model fair value for Easywell Biomedicals, Inc is 10.41 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 30.60 TWD.
What is the quality score of 1799?
Easywell Biomedicals, Inc has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.